{
  "pmcid": "7616465",
  "sha256": "1f9eb370a724bf1e6916d791868d8e09adf08fc60b6d9dab87fac9887f12d9f7",
  "timestamp_utc": "2025-11-09T16:15:04.130688+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.442704081632652,
    "reading_ease": 20.710450680272146,
    "word_count": 245
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The TWO Study (Transplantation Without Overimmunosuppression) aimed to investigate a novel approach to regulatory T-cell (Treg) therapy in renal transplant patients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Living donor kidney transplant recipients were randomized"
      },
      "Participants": {
        "score": 2,
        "evidence": "Living donor kidney transplant recipients"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized to receive autologous polyclonal Treg at week 26 posttransplantation, coupled with weaning doses of tacrolimus, (Treg therapy arm) or standard immunosuppression alone (tacrolimus and mycophenolate mofetil)"
      },
      "Objective": {
        "score": 1,
        "evidence": "aimed to investigate a novel approach to regulatory T-cell (Treg) therapy in renal transplant patients"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Primary outcomes were patient survival and rejection-free survival"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomized to receive autologous polyclonal Treg"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "we report the unique cohort of 7 patients who underwent the original randomized controlled trial protocol"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Patient and transplant survival was 100%. Acute rejection-free survival was 100% in the Treg-treated group at 18 mo after transplantation"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}